{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"55.3","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"55.3","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"23.5","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"33.1","value":"0.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"41.5","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"DLTs were defined as any of the following assessed as treatment-related by investigator (with pre-specified exceptions): Grade (Gr) 4 non-hematologic toxicity; Gr 3 non-hematologic toxicity; Gr 3 or Gr 4 non-hematologic laboratory value if: clinically significant medical intervention was required to treat the participant, the abnormality led to hospitalization, the abnormality persisted for \\>1 week, electrolyte imbalances that lasted \\>48 hours despite optimal therapy, or the abnormality resulted in a drug-induced liver injury; Gr 4 neutropenia and/or thrombocytopenia lasting \\>14 days; \\>2 week-delay in starting Cycle 2 due to treatment-related toxicity; treatment-related toxicity resulting in treatment discontinuation during DLT evaluation period; missing \\>25% of MK-0482 dose during DLT evaluation period resulting from treatment-related adverse event (AE); or Gr 5 toxicity. The percentage of participants that experienced a DLT was reported for each arm.","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \\[Q3W\\]) for up to 35 cycles (approximately 24 months).","id":"OG000","title":"MK-0482 7.5 mg Q3W"},{"description":"Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG001","title":"MK-0482 25 mg Q3W"},{"description":"Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG002","title":"MK-0482 75 mg Q3W"},{"description":"Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG003","title":"MK-0482 225 mg Q3W"},{"description":"Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG004","title":"MK-0482 750 mg Q3W"}],"paramType":"NUMBER","populationDescription":"The DLT evaluable population included all allocated participants in Part 1 (dose escalation) who received at least 1 dose of study intervention and met the criteria for DLT evaluability (i.e finished Cycle 1 without a DLT, or experienced a DLT in Cycle 1).","reportingStatus":"POSTED","timeFrame":"Cycle 1 (up to 21 days)","title":"Percentage of Participants Who Experienced a Dose-Limiting Toxicity (DLT)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}